nach oben

Erschienen in:

01.06.2006 | Original Article

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

verfasst von: Keiichi Fujiwara, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Katsuyuki Hotta, Shigeki Umemura, Keisuke Sugimoto, Takuo Shibayama, Haruhito Kamei, Shingo Harita, Niro Okimoto, Mitsune Tanimoto

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients and methods: Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1–3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m²/day, while cisplatin was fixed at the dose of 20 mg/m²/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Results: Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m²/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m²/day with cisplatin 20 mg/m²/day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. Conclusion: The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.

Ardizzoni A, Grossi F (2000) Update on the treatment of small cell lung cancer (SCLC). Ann Oncol 11(Suppl 3):101–108CrossRefPubMed

Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A (2005) Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23(3):569–575CrossRefPubMed

Ardizzoni A, Manegold C, Gaafar R, Buchholdz E, Debruyne C, Damen S, Curran D, King K, Giaconne G (1999) Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive and refractory small cell lung cancer (SCLC): An EORTC LCCG phase II study. Proc Am Soc Clin Oncol 18:471a (Abstr 1817)

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP (2000) A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 79(3):495–498CrossRefPubMed

Evans WK, Radwi A, Tomiak E, Logan DM, Martins H, Stewart DJ, Goss G, Maroun JA, Dahrouge S (1995) Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18(2):149–155PubMedCrossRef

Findlay MP, Griffin AM, Raghavan D, McDonald KE, Coates AS, Duval PJ, Gianoutsos P (1991) Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 27(12):1597–1601PubMedCrossRef

Greco FA (2003) Topotecan as first-line therapy for small cell lung cancer. Lung Cancer 41(Suppl 4):S9–S16CrossRefPubMed

Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48(7):1722–1726PubMed

Johnson BE (2002) Management of small cell lung cancer. Clin Chest Med 23(1):225–239CrossRefPubMed

10.

Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1998) Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 82(5):836–841CrossRefPubMed

11.

Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D (1994) Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21(3 Suppl 6):23–30PubMed

12.

Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ (1998) Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol 16(10):3302–3309PubMed

13.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79(1):116–119CrossRefPubMed

14.

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10(8):1225–1229PubMed

15.

Matsui K, Masuda N, Fukuoka M, Yana T, Hirashima T, Komiya T, Kobayashi M, Kawahara M, Atagi S, Ogawara M, Negoro S, Kudoh S, Furuse K (1998) Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 77(11):1961–1965PubMed

16.

Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL (1994) Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 12(12):2743–2750PubMed

17.

Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83(16):1164–1168PubMedCrossRef

18.

Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2):85–91

19.

Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N (1999) Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 17(11):3540–3545PubMed

20.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655PubMedCrossRef

21.

Radford JA, Ryder WD, Dodwell D, Anderson H, Thatcher N (1992) Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A(1):81–86PubMed

22.

Raymond E, Burris HA, Rowinsky EK, Eckardt JR, Rodriguez G, Smith L, Weiss G, Von Hoff DD (1997) Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 8(10):1003–1008CrossRefPubMed

23.

Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC (1996) Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14(12):3074–3084PubMed

24.

Saltz L, Kanowitz J, Schwartz G, Kelsen D, Eng M, Baiano D, Spriggs D (1995) Phase I trial of cisplatin (DDP) plus topotecan (T) on a daily ×5 schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:475 (Abstr 1541)

25.

Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14(8):2345–2352PubMed

26.

Seifart U, Jensen K, Ukena D, Lorenz S, Petrasch S, Fuhr HG, Keppler U, Neubauer A, Staab HJ, Wolf M (2001) Topotecan (T)/Cisplatin (DDP) 3 Days Versus Topotecan/Cisplatin 5 Days in Patients with metastatic small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 20:A1272

27.

Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, Paul K (1994) Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 42(1):64–70PubMed

28.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMed

Titel: A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer
verfasst von: Keiichi Fujiwara
Hiroshi Ueoka
Katsuyuki Kiura
Masahiro Tabata
Nagio Takigawa
Katsuyuki Hotta
Shigeki Umemura
Keisuke Sugimoto
Takuo Shibayama
Haruhito Kamei
Shingo Harita
Niro Okimoto
Mitsune Tanimoto
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0117-1

Springer Medizin

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice

Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study

Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie